The current technology utilized to screen clones for for cell line development impacts the risk level throughout a cell line development campaign. Biologics pipelines are producing increasingly complex molecules that require more sophisticated measurements, and CHO cell line selection is a painful bottleneck in biotherapeutic development, particularly for complex molecules like bispecifics.
The Beacon and Beacon Select optofluidic systems accelerate cell line development while alleviating these challenges by offering rapid cloning, screening, and selection of CHO cell lines. Widely used by top pharmaceutical firms and CDMOs, these systems enhance workflow efficiency, allowing 4X faster throughput and cutting the development time in half while ensuring >99% monoclonality for FDA filings and higher titer clones. Additionally, the Opto® Assure assays for cell line development on the Beacon platform quickly identify quality clones, reducing costs and improving success rates during the scale up process.
Confident results in less time
of Cell Line Development
Reduce Timelines While Selecting More Productive Clones
The Beacon and Beacon Select optofluidic systems enable high throughput cloning, screening, and selection of top-performing CHO cell lines in just days. Replace 8-12 weeks of onerous well plate steps with Opto® CLD on the Beacon optofluidic systems. Screen thousands of clones in parallel and select top clones for even complex molecules like bispecific antibodies and non-antibody proteins.
Microfluidic chip-based single-cell cloning to accelerate biologic production timelines Diep J et al., Biotechnology Progress.
Combined approach of selective and accelerated cloning for microfluidic chip-based system increases clone specific productivityDesmurget C, et al., Biotechnology Journal.
Leveraging Innovative Technologies to Accelerate Biologics DevelopmentJoaquina Mascarenhas, PhD, at Thermo Fisher Scientific
The Beacon platform enables the rapid measurement and selection of the high-performing clones, leveraging best-in-class assay capabilities to assess monoclonality, growth, productivity, quality, and stability within weeks of single cell cloning to compress CLD timeliness.
Superior assurance of >99% monoclonality for regulatory submissions
As the cells expand in the chamber microenvironment, fluorescence-based assays can be performed at multiple time points to identify clones with desired attributes
Productivity information at the earliest stages of cell line development
Discern producing clones with a diffuse fluorescent signal gradient during product secretion assays
Selection based on product quality, not just productivity
Direct detection of insoluble product aggregates within days of single cell cloning, confidently identifying and selecting clones that develop better production cell lines faster.
Bring Product Quality Assessment into Early Clone Selection with the Opto™ Assure Aggregation Assay
SpotLight™ Reagents to Expedite Productivity and Quality Screening in Cell Line Development Workflows
Integrated imaging capability in combination with in-process quality controls provide superior end to end monoclonality assurance compared to microtiter plate based cloning approaches. The Beacon platform has been validated by the CLD community and regulatory bodies, with 38% of CLD users adopting the platform and achieving successful IND filings, and robust demonstration of >99% monoclonality with robust statistical analyses.
FDA-Accepted Monoclonality Assurance on the Beacon® Optofluidic System for Cell Line Development
Assuring Clonality on the Beacon Digital Cell Line Development Platform
The Beacon platform is a highly integrated solution for the rapid measurement and selection of clones, freeing scientists’ time while delivering robust characterization of clone performance.
Up to 10 times more
projects per year.
Millions in enabled revenue.
Increase CDMO Revenue with the Opto Cell Line Development Workflow
The Opto® Cell Line Development Workflow
Cell Line Development Platform
High Performing Clones
into the Clinic
At the core of the Beacon system is a combination of optics and nanofluidics called optofluidics. The OptoSelect® chips replace typical well plates. Each OptoSelect chip contains thousands of NanoPen® chambers, which replace wells on a microplate. This is where cells are selectively placed, cultured and characterized using a myriad of proprietary Beacon Platform assays.
- Comprehensive assays:
Assess monoclonality, growth, productivity, quality, and stability within weeks of single cell cloning - IND-validated monoclonality:
- Powerful automation
- Measure antibody production from 1000s of clones
Your Cell Line Development Research
Complete the form to connect with us and discover how the Beacon technology can enhance your Cell Line Development programs.
Our expert team will be able to answer your questions, show you how the Beacon system works, and share the most relevant datasheets & case studies for your research.